A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

This study has been terminated.
(The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.)
Sponsor:
Information provided by (Responsible Party):
Biogen
ClinicalTrials.gov Identifier:
NCT01416181
First received: July 21, 2011
Last updated: July 15, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2016
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 15, 2016